UnitedHealth Group (UNH) Stock Today: Price, West Virginia Opioid Lawsuit, Guidance Raise and 2026 Forecasts

Date: December 9, 2025
Ticker: UnitedHealth Group Incorporated (NYSE: UNH)

UnitedHealth Group stock is trading roughly flat on Tuesday, even as investors digest fresh legal headlines, a recent earnings guidance upgrade, and a broad range of Wall Street forecasts that still point to upside for the health‑insurance and services giant.

As of mid‑afternoon, UNH is changing hands around $324 per share, up a fraction on the day, after closing Monday at $323.62. ^[1] Despite a brutal drawdown earlier this year, the stock has delivered an estimated mid‑30% total return year‑to‑date, more than double the S&P 500’s gain over the same period. ^[2]

At the same time, UnitedHealth faces intensifying scrutiny: a new opioid‑related lawsuit from West Virginia, ongoing Department of Justice investigations into its Medicare business, and mounting political pressure around pharmacy benefit managers (PBMs). ^[3]

Below is a detailed look at how those cross‑currents are shaping the UNH stock story on December 9, 2025.

Key Takeaways for UNH Stock on December 9, 2025

• Price & performance: UNH trades near $324, with a trailing P/E around 17x and market value just under $293 billion. ^[4]
• Fresh legal overhang: West Virginia has sued UnitedHealth and its Optum PBM over alleged roles in the opioid crisis, adding to existing DOJ probes of Medicare Advantage billing. ^[5]
• Fundamentals improving: Q3 2025 revenue grew 12% year‑on‑year to $113.2 billion, with adjusted EPS of $2.92 and higher full‑year guidance for 2025. ^[6]
• Guidance & growth: Management now expects adjusted 2025 EPS of at least $16.25, and analysts see 2026 profit around $17.6 per share, implying high‑single‑digit earnings growth. ^[7]
• Wall Street view: Consensus 12‑month price targets cluster around $380–395—roughly 19% upside—but opinions are split between “Buy”, “Hold” and a minority of “Sell” ratings. ^[8]
• Technical setup: Short‑term trading models currently flag UNH as a “sell candidate”, expecting potential further weakness over the next three months despite improving fundamentals. ^[9]

1. UnitedHealth Stock Today: Price, Valuation and Recent Moves

Intraday on Tuesday, UnitedHealth Group (UNH) is trading around $324.10, with the session’s high and low roughly $326.23 and $322.74 respectively. Volume is modest at about 1.5 million shares.

On basic valuation metrics:

• Market cap: ≈ $292–293 billion ^[10]
• Trailing P/E: about 16.9x ^[11]
• P/E/G ratio: roughly 2.2 (using consensus growth estimates) ^[12]
• Beta: ~0.43, indicating lower volatility than the broader market. ^[13]

Using the company’s new 2025 adjusted EPS outlook of at least $16.25, UNH is trading around 20x forward 2025 earnings, and roughly 18–19x based on the 2026 analyst EPS consensus of about $17.6 per share. ^[14] That’s a premium to some smaller managed‑care peers, but below where UnitedHealth historically traded when growth was more predictable.

Price history underscores this year’s drama:

• Current share price ≈ $323–324
• 52‑week high: about $606
• 52‑week low: roughly $235
• 1‑year share change: down more than 40% from a year ago, despite the more recent rally. ^[15]

In other words, UnitedHealth has staged a strong recovery from its 2025 lows but is still trading far below its prior peak.

2. New Legal Shock: West Virginia’s Opioid Lawsuit Against Optum

The most prominent fresh headline this week is a federal lawsuit filed by West Virginia against UnitedHealth Group and its PBM subsidiary Optum.

According to the complaint, the state alleges that Optum: ^[16]

• Worked with other drug‑industry players to loosen safeguards on opioid prescribing and distribution.
• Used its control over drug formularies and coverage decisions to increase daily dosage limits and penalize payers that tried to restrict opioid dispensing.
• Failed to use its “gatekeeper” role to curb excessive opioid prescriptions despite having the power to limit coverage.
• Dispensed opioids through mail‑order pharmacies without adequate oversight.

West Virginia is pursuing claims under state consumer‑protection laws, federal RICO statutes and negligence theories. The suit comes as PBMs face broader scrutiny over their role in drug pricing and utilization, and follows prior actions against other PBMs such as Express Scripts. ^[17]

Optum previously paid $20 million to settle separate federal allegations that it ignored warning signs when shipping opioids from a California mail‑order pharmacy. ^[18] While today’s case does not immediately alter UnitedHealth’s earnings outlook, it adds to a growing cluster of legal risks and could eventually lead to settlements, fines, or changes in PBM economics.

For investors, this lawsuit reinforces that Optum Rx, a key profit driver within UnitedHealth, sits squarely in the cross‑hairs of both litigators and policymakers.

3. DOJ Investigations and Regulatory Pressure

Beyond West Virginia’s suit, UnitedHealth is already under federal civil and criminal investigation over its Medicare Advantage billing practices.

• In February, reports indicated that the U.S. Department of Justice opened a new civil fraud probe into how UnitedHealth documents diagnoses that increase risk‑adjusted payments from Medicare for its Medicare Advantage (MA) plans. ^[19]
• Advocacy groups later highlighted a Wall Street Journal report suggesting the DOJ is also examining potential criminal Medicare fraud, focused on MA business practices. ^[20]

UnitedHealth’s response, published in July, emphasized that the company proactively contacted the DOJ, is cooperating fully, and believes its Medicare and PBM practices are compliant. The company cites CMS audits and a court‑appointed special master in earlier civil litigation who found no evidence supporting prior DOJ allegations, but also acknowledges that it “cannot predict the outcome of the government investigations.” ^[21]

At the same time, Congress continues to work on PBM reform packages that would reshape incentives in the drug supply chain, with proposals aimed at increasing transparency and potentially limiting PBM spread pricing and rebate structures. ^[22] For Optum Rx, regulatory changes could compress margins over time, even if they expand volumes.

Taken together, the DOJ probes and PBM reforms mean legal and policy risk remains one of the biggest overhangs on UNH stock.

4. Q3 2025 Earnings: Beat and Guidance Raise

Fundamentally, UnitedHealth’s latest quarter looked solid:

• Revenue: $113.2 billion, up 12% year‑over‑year.
• GAAP EPS: $2.59; adjusted EPS: $2.92, slightly ahead of analyst expectations.
• Earnings from operations: $4.3 billion, implying a net margin of about 2.1% as the company absorbs elevated medical costs and restructuring efforts.
• Medical care ratio (MCR): 89.9%, high but in line with internal expectations.
• Operating cost ratio: 13.5%, reflecting investments to support future growth. ^[23]

By business line:

• UnitedHealthcare (the insurance arm) saw revenue climb 16% to $87.1 billion, serving roughly 50.1 million U.S. members—almost 800,000 more than a year earlier. ^[24]
• Optum grew revenue about 8% to $69.2 billion, powered largely by Optum Rx, whose revenue increased around 16% thanks to higher prescription volumes. Optum Health, which operates clinics and value‑based care, posted flat revenue and weaker margins. ^[25]

On the earnings call, new/returning CEO Stephen Hemsley and the leadership team framed Q3 as a first step in a multi‑year turnaround:

• UnitedHealth raised its 2025 net EPS guidance to at least $14.90, and adjusted EPS to at least $16.25, up from a prior “at least $16.00” target established in July. ^[26]
• Management aims for a return to growth in 2026, with accelerating, potentially double‑digit earnings growth by 2027, even while exiting some unprofitable Medicare Advantage and Affordable Care Act (ACA) markets and repricing others more aggressively. ^[27]

Notably, UnitedHealth is willing to sacrifice membership for margins:

• The company expects to lose about 1 million Medicare Advantage members in 2026 as it exits or reprices certain plans. ^[28]
• In ACA exchanges, UnitedHealthcare has secured >25% average premium increases in the 30 states where it participates, but anticipates reducing its ACA enrollment by roughly two‑thirds as a result. ^[29]

For investors, that trade‑off underscores the new strategy: price for profitability, not for maximum market share.

5. Dividend and Balance Sheet

UnitedHealth remains a dividend payer with a long history of annual increases:

• The board declared a quarterly dividend of $2.21 per share, with an ex‑dividend date of December 8, 2025 and payment scheduled for December 16, 2025. ^[30]
• At today’s share price, that equates to an annualized dividend of $8.84 and a yield close to 2.7%. ^[31]
• MarketBeat data peg the dividend payout ratio near 46% of earnings, leaving room for reinvestment and potential future increases. ^[32]

The balance sheet also remains solid:

• Debt‑to‑equity ratio: about 0.71.
• Current and quick ratios: both around 0.82.
• Debt‑to‑capital: roughly 44% as of Sept. 30, 2025, unchanged after closing the Amedisys home‑health acquisition. ^[33]

UnitedHealth therefore still looks like a financially sturdy dividend growth story, albeit one navigating significant operational and regulatory turbulence.

6. What Are Analysts Saying About UNH?

Consensus Targets and Ratings

Across major data providers, Wall Street remains generally constructive on UnitedHealth, though not universally bullish:

• MarketBeat: Average 12‑month price target about $385.5, implying ~19% upside from the low‑$320s; consensus rating currently “Hold”, based on a mix of Buy, Hold and a few Sell calls. ^[34]
• TipRanks: Average target around $393.9, with analysts seeing just over 19% upside and most ratings in the Buy zone. ^[35]
• QuiverQuant: Median target about $372, based on 36 price targets. ^[36]
• Public.com: Summarizes 23 analysts with a “Buy” consensus and a 2025 price prediction near $385.7. ^[37]
• Benzinga: A broader, longer‑dated sample shows a consensus target above $420, with a bull‑case target in the mid‑$600s and a bear‑case near $198, highlighting wide disagreement on long‑term earnings power. ^[38]

Valuation services also weigh in:

• Simply Wall St estimates a fair value around $388.5 per share—roughly 17% above the current price—assuming mid‑single‑digit annual revenue growth and margin recovery. ^[39]
• Community narratives on the same platform show bullish fair values above $490 and bearish scenarios around $198, depending on assumptions about Medicare scrutiny, PBM regulation and health‑care cost trends. ^[40]

Recent Analyst Commentary

Recent analyst and independent commentary splits into two broad camps:

• Recovery bulls: At least one recent Seeking Alpha article characterizes UnitedHealth as a “healthcare fortress” whose worst year may be behind it, arguing that repricing, cost controls and operational changes position the company for renewed earnings growth from 2026 onward. ^[41]
• Cautious or bearish voices: Another recent analysis downgraded the stock, highlighting lingering uncertainty from ACA subsidy changes, elevated care utilization, the DOJ probes and PBM reform risk. ^[42]

Most agree on one point: UnitedHealth’s long‑term franchise remains strong, but the path back to its historical steady‑growth profile is bumpier and more politically exposed than it has been in years.

7. Technical and Short‑Term Trading View

From a purely technical perspective, UNH still looks fragile despite its rebound.

Technical research service StockInvest.us notes that: ^[43]

• The stock fell 2.2% on Monday (Dec. 8) from $330.91 to $323.62 and has declined three sessions in a row.
• UNH sits in the middle of a broad, downward‑sloping short‑term trend, with the model projecting a potential 8–9% decline over the next three months, implying a range of roughly $276–309 under current conditions.
• Moving‑average signals skew negative, with both short‑ and long‑term averages pointing to near‑term weakness, even as the three‑month MACD remains in “buy” territory.
• The service currently labels UNH a “sell candidate”, expecting the stock to “perform weakly” in coming weeks barring a sentiment shift.

Support and resistance levels are relatively tight:

• Near‑term support: around $321–322 based on accumulated volume.
• Resistance: significant overhead between the mid‑$340s and high‑$360s. ^[44]

Short‑term traders, in other words, are still treating UNH as a range‑bound and somewhat pressured name even as fundamentals stabilize.

8. Institutional Investor Activity: Mixed but Deep Support

New 13F filings summarized by MarketBeat on December 9 show heavy institutional ownership and mixed positioning: ^[45]

• Axa S.A. trimmed its stake by about 34.6%, selling over 155,000 shares and ending the quarter with roughly 293,000 shares worth about $91 million. ^[46]
• Gabelli Funds cut its position by nearly 25%, to just over 29,000 shares. ^[47]
• State Street Corp, a major index and custody player, reduced its UNH holdings slightly (down 0.9%) but still owns nearly 45 million shares, representing about 5% of the company. ^[48]
• On the other side of the ledger, London & Capital Asset Management boosted its holdings by 35.6% in Q2 to roughly 118,500 shares, making UNH its 11th‑largest holding, while Daiwa Securities Group increased its stake by about 2.2%. ^[49]
• Large investors like Norges Bank, Dodge & Cox, Wellington Management, Amundi and Natixis have also built substantial positions, leaving overall institutional ownership close to 88% of outstanding shares. ^[50]

These flows suggest no clear institutional stampede in or out of the stock. Many long‑only funds appear to be averaging in at lower valuations, while others trim exposures amid legal and policy uncertainty.

9. Strategic Shifts: Amedisys, Optum Health and Board Changes

UnitedHealth’s strategy in 2025 has revolved around repairing profitability and reshaping its footprint:

• The company completed its $3.3 billion acquisition of home‑health provider Amedisys this summer, further expanding Optum’s presence in care delivery and post‑acute services. ^[51]
• At Optum Health, management is narrowing provider networks, exiting unprofitable members and refocusing on value‑based models after rapid expansion weighed on margins. The unit plans to shrink value‑based membership by about 10% next year to rebuild profitability. ^[52]
• Governance‑wise, UnitedHealth recently added Scott Gottlieb, M.D.—former head of the U.S. Food and Drug Administration—to its board of directors, a move investors view as bolstering regulatory and policy expertise. ^[53]

These moves support the narrative that UnitedHealth is resetting its portfolio around more disciplined pricing, targeted growth and closer regulatory navigation.

10. Big Picture: What Could Move UNH Stock Next?

Investors watching UNH over the coming weeks and months will likely focus on several key catalysts:

1. Q4 2025 earnings and 2026 guidance
   • UnitedHealth is slated to report its next results around mid‑January 2026, when management is expected to publish a detailed 2026 outlook. ^[54]
   • Markets will scrutinize whether the company can deliver on margin recovery while absorbing expected membership losses in Medicare Advantage and ACA exchanges.
2. Developments in DOJ and PBM investigations
   • Any indications of settlement, escalation, or narrowing of scope in the DOJ probes, or early rulings in related litigation, could swing sentiment meaningfully. ^[55]
   • Progress—or delays—in PBM reform legislation will influence long‑term expectations for Optum Rx margins. ^[56]
3. Resolution or expansion of the West Virginia opioid case
   • Motions to dismiss, class certifications, or settlement talks could all become stock‑moving headlines, particularly if more states follow suit. ^[57]
4. Industry‑wide trends in medical costs
   • If utilization in Medicare, Medicaid and ACA markets stabilizes or moderates, investors may become more confident in UnitedHealth’s repricing strategy and its ability to grow earnings from 2026 onward. ^[58]

11. Key Risks for UNH Shareholders

Even with improving fundamentals, several risks remain front‑and‑center for UnitedHealth:

• Regulatory & legal – DOJ civil and criminal investigations, the new opioid suit, and PBM reforms all carry the risk of fines, settlements, or business model changes that could erode profitability. ^[59]
• Medical cost trends – Elevated utilization in Medicare, Medicaid and ACA markets remains a major swing factor. If costs outpace pricing, margin recovery could be delayed. ^[60]
• Execution risk at Optum & Amedisys – Integrating home‑health operations, narrowing networks and re‑engineering value‑based care contracts is complex; missteps could weigh on earnings. ^[61]
• Political risk – Changes in federal policy on Medicare Advantage, ACA subsidies or drug pricing could significantly alter revenue and margin trajectories. ^[62]
• Valuation & sentiment – After a sharp rebound from its lows, UNH still trades at a premium multiple to slower‑growing insurers. If earnings disappoint again, the stock could be vulnerable to another de‑rating. ^[63]

12. Bottom Line: How Does UNH Look on December 9, 2025?

On today’s information, UnitedHealth Group stock sits at a crossroads:

• The fundamental story is improving: Q3 results beat expectations, 2025 guidance has been nudged higher, management is repricing risky business, and the balance sheet and dividend remain robust. ^[64]
• Yet legal and regulatory uncertainty is unusually high, with fresh litigation from West Virginia, ongoing DOJ probes, and intensifying PBM scrutiny. ^[65]
• Wall Street forecasts generally see mid‑teens to 20% upside over the next year, but the range of outcomes is wide, and some technical models still flag UNH as a near‑term sell. ^[66]

For long‑term investors, the question is whether UnitedHealth’s scale, diversification and execution track record can offset the policy and legal headwinds now circling its core franchises.

As always, this article is for informational and educational purposes only and does not constitute financial advice. Anyone considering an investment in UNH should evaluate their own risk tolerance, time horizon and diversification needs, and consider consulting a qualified financial adviser.

References

1. stockinvest.us, 2. finance.yahoo.com, 3. www.reuters.com, 4. www.marketbeat.com, 5. www.reuters.com, 6. www.unitedhealthgroup.com, 7. www.unitedhealthgroup.com, 8. www.marketbeat.com, 9. stockinvest.us, 10. www.marketbeat.com, 11. www.marketbeat.com, 12. www.marketbeat.com, 13. simplywall.st, 14. www.unitedhealthgroup.com, 15. simplywall.st, 16. www.reuters.com, 17. www.reuters.com, 18. www.reuters.com, 19. www.reuters.com, 20. medicareadvocacy.org, 21. www.unitedhealthgroup.com, 22. www.washingtonpost.com, 23. www.unitedhealthgroup.com, 24. www.unitedhealthgroup.com, 25. www.unitedhealthgroup.com, 26. www.unitedhealthgroup.com, 27. www.reuters.com, 28. www.healthcaredive.com, 29. www.healthcaredive.com, 30. simplywall.st, 31. www.marketbeat.com, 32. www.marketbeat.com, 33. www.unitedhealthgroup.com, 34. www.marketbeat.com, 35. www.tipranks.com, 36. www.quiverquant.com, 37. public.com, 38. www.benzinga.com, 39. simplywall.st, 40. simplywall.st, 41. seekingalpha.com, 42. seekingalpha.com, 43. stockinvest.us, 44. stockinvest.us, 45. www.marketbeat.com, 46. www.marketbeat.com, 47. www.marketbeat.com, 48. www.marketbeat.com, 49. www.marketbeat.com, 50. www.marketbeat.com, 51. www.healthcaredive.com, 52. www.healthcaredive.com, 53. simplywall.st, 54. stockinvest.us, 55. www.reuters.com, 56. seekingalpha.com, 57. www.reuters.com, 58. www.healthcaredive.com, 59. www.reuters.com, 60. www.healthcaredive.com, 61. www.healthcaredive.com, 62. www.healthcaredive.com, 63. simplywall.st, 64. www.unitedhealthgroup.com, 65. www.reuters.com, 66. www.marketbeat.com